Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 477-481

  Takimoto, Chris H ^a   Lu, Zhi Hong ^b   Zhang, Ruiwen ^b   Liang, Michael D ^a   Larson, Lydia V ^a   Cantilena Jr , Louis R ^c   Grem, Jean L ^a   Allegra, Carmen J ^a   Diasio, Robert B ^b   Chu, Edward ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; THYMIDINE;

ADULT; ARTICLE; BRAIN DISEASE; CANCER; CASE REPORT; ENZYME DEFICIENCY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

BRAIN DISEASES; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES;

EID: 9044246668     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. J. Clin. Invest., 81 47-51, 1988.
2. Harris, B. E., Carpenter, J. T., and Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency a potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
3. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53: 5433-5438, 1993.
4. Diasio, R. B. Genetic polymorphism of dihydropyrimidine dehydrogenase:Implications for 5-fluorouracil metabolism and toxicity. Proc. Am. Assoc. Cancer Res., 35: 688, 1994.
5. Diasio, R. B., and Lu, Z-H. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol., 12: 2239-2242. 1994
6. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F., and Milano, G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12: 2248-2253, 1994.
7. Grem, J. L. 5-Fluoropyrimidines. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, Second Edition, pp. 149-211. Philadelphia: Lippincott-Raven, 1996.
8. Lynch, H. T., Droszcz, C. P., Albano, W. A., and Lynch, J. F. Organic brain syndrome secondary to 5-fluorouracil toxicity. Dis. Colon Rectum, 24: 130-131, 1981.
9. Fassas, A. B. T., Gattani, A. M., and Morgello, S. Cerebral demyelination with 5 fluorouracil and levamisole. Cancer Invest., 12: 379-383, 1994
10. Bradford, M. A. Rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 258-264, 1976.
11. Sommadossi, J. P., Gewirtz, D. A., Diasio, R. B., Aubert, C., Cano, J. P., and Goldman, I. D. Rapid catabolism of 5-fluorouracil in freshly isolated hepatocytes as analyzed by high performance liquid chromatography. J. Biol. Chem., 257: 8171-8176, 1982.
12. Lu, Z-H., Zhang, R., and Diasio, R. B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem., 267: 17102-17109, 1992.
13. Au, J. L., Rustum, Y. M., Ledesma, E. J., Mittelman, A., and Creaven, P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res., 42: 2930-2937, 1982.
14. Anderson, L. W., Parker, R. J., Collins, J. M., Ahlgren, J. D., Wilkinson, D., Strong, J. M. Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J. Chromatog., 581: 195-201, 1992.
15. Amin, G., Shahinian, H., Miller, D., Vukelja, S., Zhang, R., Lu, Z., Diasio, R. B. Severe neurotoxicity following 5-fluorouracil (FUra) chemotherapy in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. Proc. Am. Soc. Clin. Oncol., 14: 169, 1995
16. Tuchman, M., Stoeckeler, J S., Kiang, D. T., O'Dea, R. F., Ramnaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyriminuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
17. Fleming, R. A., Milano, G. A., Gaspard, M. H., Bargnous, P. J., Thyss, A., Plagne, R., Renée, N., Schneider, M., and Demard, F. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur. J. Cancer, 29A: 740-744, 1993.
18. Van Groeningen, C. J., Peters, G. J., and Pinedo, H. M. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann. Oncol., 4: 317-320, 1993.
19. Grem, J. L , King, S. A., Sorensen, J. M., and Christian, M. C. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest. New Drugs, 9: 281-290, 1991.
20. Koenig, H., and Patel, A. Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate Arch. Neurol., 23: 155-160, 1970.